keyword
https://read.qxmd.com/read/38661207/is-shorter-also-better-in-the-treatment-of-clostridioides-difficile-infection
#61
JOURNAL ARTICLE
M Duricek, K Halmova, M Krutova, B Sykorova, J Benes
OBJECTIVES: To assess the effectiveness of shortened regimens of vancomycin or fidaxomicin in the treatment of Clostridioides difficile infection (CDI). METHODS: Adult patients with CDI hospitalized from January 2022 to May 2023 were included in this observational study. In patients with CDI treated with vancomycin or fidaxomicin, antibiotic treatment was discontinued after either 5 or 7 days of vancomycin or 5 days of fidaxomicin if there was a clinical response and improvement in laboratory parameters...
April 25, 2024: Journal of Antimicrobial Chemotherapy
https://read.qxmd.com/read/38661188/machine-learning-based-prediction-models-for-c-difficile-infection-a-systematic-review
#62
JOURNAL ARTICLE
Raseen Tariq, Sheza Malik, Renisha Redij, Shivaram Arunachalam, William A Faubion, Sahil Khanna
BACKGROUND: Despite research efforts, predicting Clostridioides difficile incidence and its outcomes remains challenging. This systematic review aimed to evaluate the performance of machine-learning (ML) models in predicting CDI incidence and complications using clinical data from electronic health records. METHODS: We conducted a comprehensive search of databases (OVID, Embase, MEDLINE ALL, Web of Science, and Scopus) from inception up to September 2023. Studies employing ML techniques for predicting CDI or its complications were included...
April 25, 2024: Clinical and Translational Gastroenterology
https://read.qxmd.com/read/38659900/elucidating-human-gut-microbiota-interactions-that-robustly-inhibit-diverse-clostridioides-difficile-strains-across-different-nutrient-landscapes
#63
Jordy Sulaiman, Jaron Thompson, Yili Qian, Eugenio Vivas, Christian Diener, Sean M Gibbons, Nasia Safdar, Ophelia S Venturelli
The human gut pathogen Clostridioides difficile displays extreme genetic variability and confronts a changeable nutrient landscape in the gut. We mapped gut microbiota inter-species interactions impacting the growth and toxin production of diverse C. difficile strains in different nutrient environments. Although negative interactions impacting C. difficile are prevalent in environments promoting resource competition, they are sparse in an environment containing C. difficile-preferred carbohydrates. C. difficile strains display differences in interactions with Clostridium scindens and the ability to compete for proline...
April 17, 2024: bioRxiv
https://read.qxmd.com/read/38659636/assessing-engraftment-following-fecal-microbiota-transplant
#64
Chloe Herman, Bridget M Barker, Thais F Bartelli, Vidhi Chandra, Rosa Krajmalnik-Brown, Mary Jewell, Le Li, Chen Liao, Florencia McAllister, Khemlal Nirmalkar, Joao B Xavier, J Gregory Caporaso
Fecal Microbiota Transplant (FMT) is an FDA approved treatment for recurrent Clostridium difficile infections, and is being explored for other clinical applications, from alleviating digestive and neurological disorders, to priming the microbiome for cancer treatment, and restoring microbiomes impacted by cancer treatment. Quantifying the extent of engraftment following an FMT is important in determining if a recipient didn't respond because the engrafted microbiome didn't produce the desired outcomes (a successful FMT, but negative treatment outcome), or the microbiome didn't engraft (an unsuccessful FMT and negative treatment outcome)...
April 10, 2024: ArXiv
https://read.qxmd.com/read/38655018/a-retrospective-chart-review-assessing-antibiotic-treatment-of-hospitalized-patients-with-discordant-clostridioides-difficile-assays-in-an-urban-hospitalized-setting
#65
JOURNAL ARTICLE
Clare Stoddart, Irene Kuo, Matthew A Spence, Tara N Palmore
Clostridioides difficile infection (CDI) threatens vulnerable populations in health care. Two-step testing improves specificity, avoiding over-treatment. This study analyzed inpatient records to estimate diagnostic outcomes and identify characteristics associated with treatment after discordant testing. Among discordant patients, those aged 65+ years were significantly more likely to be prescribed antibiotics (67% vs 39%).
2024: Antimicrob Steward Healthc Epidemiol
https://read.qxmd.com/read/38653643/post-infectious-ibs-following-clostridioides-difficile-infection-role-of-microbiota-and-implications-for-treatment
#66
REVIEW
Dana Taghaddos, Zarwa Saqib, Xaiopeng Bai, Premysl Bercik, Stephen M Collins
Up to 25% of patients recovering from antibiotic-treated Clostridioides difficile infection (CDI) develop functional symptoms reminiscent of Post-Infectious Irritable Bowel Syndrome (PI-IBS). For patients with persistent symptoms following infection, a clinical dilemma arises as to whether to provide additional antibiotic treatment or to adopt a conservative symptom-based approach. Here, we review the literature on CDI-related PI-IBS and compare the findings with PI-IBS. We review proposed mechanisms, including the role of C...
April 22, 2024: Digestive and Liver Disease
https://read.qxmd.com/read/38653188/active-surveillance-pharmacovigilance-for-clostridioides-difficile-infection-and-gastrointestinal-bleeding-an-analytic-framework-based-on-case-control-studies
#67
JOURNAL ARTICLE
Ravy K Vajravelu, Amy R Byerly, Robert Feldman, Scott D Rothenberger, Robert E Schoen, Walid F Gellad, James D Lewis
BACKGROUND: Active surveillance pharmacovigilance is an emerging approach to identify medications with unanticipated effects. We previously developed a framework called pharmacopeia-wide association studies (PharmWAS) that limits false positive medication associations through high-dimensional confounding adjustment and set enrichment. We aimed to assess the transportability and generalizability of the PharmWAS framework by using medical claims data to reproduce known medication associations with Clostridioides difficile infection (CDI) or gastrointestinal bleeding (GIB)...
April 22, 2024: EBioMedicine
https://read.qxmd.com/read/38651930/reduction-of-product-composition-variability-using-pooled-microbiome-ecosystem-therapy-and-consequence-in-two-infectious-murine-models
#68
JOURNAL ARTICLE
Julie Reygner, Johanne Delannoy, Marie-Thérèse Barba-Goudiaby, Cyrielle Gasc, Benoît Levast, Enora Gaschet, Laurent Ferraris, Stéphane Paul, Nathalie Kapel, Anne-Judith Waligora-Dupriet, Frederic Barbut, Muriel Thomas, Carole Schwintner, Bastien Laperrousaz, Nathalie Corvaïa
Growing evidence demonstrates the key role of the gut microbiota in human health and disease. The recent success of microbiotherapy products to treat recurrent Clostridioides difficile infection has shed light on its potential in conditions associated with gut dysbiosis, such as acute graft-versus-host disease, intestinal bowel diseases, neurodegenerative diseases, or even cancer. However, the difficulty in defining a "good" donor as well as the intrinsic variability of donor-derived products' taxonomic composition limits the translatability and reproducibility of these studies...
April 23, 2024: Applied and Environmental Microbiology
https://read.qxmd.com/read/38651406/case-series-efficacy-of-polyclonal-intravenous-immunoglobulin-for-refractory-clostridioides-difficile-infection
#69
JOURNAL ARTICLE
Sophie A Ragan, Caitlin Doyle, Neha Datta, Heather Abdic, Mark H Wilcox, Ros Montgomery, Shanika A Crusz, Yashwant R Mahida, Tanya M Monaghan
BACKGROUND: Intravenous immunoglobulin (IVIg) for Clostridioides difficile infection (CDI) no longer features in treatment guidelines. However, IVIg is still used by some clinicians for severe or recurrent CDI (rCDI) cases. The main objective of this study was to investigate the efficacy of IVIg and to identify possible predictors of disease resolution post IVIg administration for patients with CDI. METHODS: This retrospective observational cohort study of patients ≥2 years old hospitalised with severe, relapsing, or rCDI treated with IVIg therapy was performed in a large UK tertiary hospital between April 2018 and March 2023...
April 1, 2024: Antibodies
https://read.qxmd.com/read/38650404/-antibacterial-prophylaxis-with-fosfomycin-at-the-time-of-the-urethral-catheter-removal-after-radical-prostatectomy-prospective-randomized-trial
#70
JOURNAL ARTICLE
I Veliev E, A Sokolov E, Yu Metelev A, N Aliev E, S Polyakova A, V Ivkin E
AIM: To evaluate the effect of antibacterial prophylaxis using oral fosfomycin during the removal of a urethral catheter after radical prostatectomy on the development of urinary tract infection, severity of leukocyturia and bacteriuria, as well as the severity of lower urinary tract symptoms. MATERIALS AND METHODS: A single-center, non-blind, prospective, randomized controlled trial was carried out. The main group included 40 patients, and the control group included 37 patients...
March 2024: Urologii︠a︡
https://read.qxmd.com/read/38649159/impact-of-the-coronavirus-disease-2019-pandemic-on-the-incidence-of-other-infectious-diseases-in-the-hematology-hospital-in-korea
#71
JOURNAL ARTICLE
Seohee Oh, Yu-Sun Sung, Mihee Jang, Yong-Jin Kim, Hyun-Wook Park, Dukhee Nho, Dong-Gun Lee, Hyeon Woo Yim, Sung-Yeon Cho
BACKGROUND/AIMS: Since the coronavirus disease 2019 (COVID-19) outbreak, hospitals have implemented infection control measures to minimize the spread of the virus within facilities. This study aimed to investigate the impact of COVID-19 on the incidence of healthcare-associated infections (HCAIs) and common respiratory virus (cRV) infections in hematology units. METHODS: This retrospective study included all patients hospitalized in Catholic Hematology Hospital between 2019 and 2020...
April 23, 2024: Korean Journal of Internal Medicine
https://read.qxmd.com/read/38648953/the-association-between-duration-of-antibiotics-and-infectious-complications-following-radical-cystectomy-analysis-of-the-2019-2021-nsqip-database
#72
JOURNAL ARTICLE
Rachel Passarelli, John Pfail, Alain Kaldany, Kevin Chua, Benjamin Lichtbroun, Hiren V Patel, Arnav Srivastava, David Golombos, Thomas L Jang, Vignesh T Packiam, Saum Ghodoussipour
OBJECTIVES: To identify the impact of the duration of peri-operative antibiotics on infectious complications following radical cystectomy. METHODS: The National Surgical Quality Improvement Project (NSQIP) targeted database was queried for patients undergoing radical cystectomy from 2019-2021. Baseline patient characteristics were collected. Antibiotic duration was classified as <24 hours (short), 24-72 hours (intermediate) or >72 hours (long). Infectious complication data was collected including surgical site infection (SSI), urinary tract infection (UTI), organ space infection, pneumonia, sepsis, and clostridium difficile infection up to 30 days after surgery...
April 20, 2024: Urology
https://read.qxmd.com/read/38638911/gut-microbiome-changes-in-mouse-mongolian-gerbil-and-hamster-models-following-clostridioides-difficile-challenge
#73
JOURNAL ARTICLE
Shuangshuang Wan, Peijun You, Qikai Shi, Hui Hu, Lu Zhang, Leyang Chen, Ziyi Wu, Shan Lin, Xiaojun Song, Yongneng Luo, Yaxuan Wang, Feng Ju, Dazhi Jin, Yu Chen
INTRODUCTION: Clostridioides difficile infection (CDI), as well as its etiology and pathogenesis, have been extensively investigated. However, the absence of suitable CDI animal models that reflect CDI symptoms and the associated gut microbiome changes in humans has limited research progress in this field. Thus, we aimed to investigate whether Mongolian gerbils, which present a range of human pathological conditions, can been used in studies on CDI. Methods: In this study, we infected Mongolian gerbils and two existing CDI model animals, mice and hamsters, with the hypervirulent ribotype 027 C...
2024: Frontiers in Microbiology
https://read.qxmd.com/read/38631957/the-incidence-of-clostridium-difficile-infection-in-children-with-and-without-inflammatory-bowel-diseases-a-single-center-study-in-taiwan-from-2006-to-2019
#74
JOURNAL ARTICLE
Mu-Ming Chien, Mei-Hwei Chang, Kai-Chi Chang, Yen-Hsuan Ni, Jia-Feng Wu
BACKGROUND: The incidence of Clostridium difficile infection (CDI) is increasing around the world, and patients with inflammatory bowel disease (IBD) have a higher risk of obtaining CDI. The data on the incidence rate of CDI in the Asian pediatric IBD population was lacking. METHODS: We retrospectively collected data from a tertiary medical center in Taipei, Taiwan. All patients aged 1-18 years old who visited the outpatient department or were admitted to our hospital between 2006 and 2019 were included...
April 16, 2024: Journal of the Formosan Medical Association
https://read.qxmd.com/read/38622483/advancements-in-understanding-bacterial-enteritis-pathogenesis-through-organoids
#75
REVIEW
Zhengyang Wu, Hongyuan Liu, Xianli Wang
Bacterial enteritis has a substantial role in contributing to a large portion of the global disease burden and serves as a major cause of newborn mortality. Despite advancements gained from current animal and cell models in improving our understanding of pathogens, their widespread application is hindered by apparent drawbacks. Therefore, more precise models are imperatively required to develop more accurate studies on host-pathogen interactions and drug discovery. Since the emergence of intestinal organoids, massive studies utilizing organoids have been conducted to study the pathogenesis of bacterial enteritis, revealing new mechanisms and validating established ones...
April 15, 2024: Molecular Biology Reports
https://read.qxmd.com/read/38621586/c-difficile-biomarkers-pathogenicity-and-detection
#76
REVIEW
Sepideh Ziaei Chamgordani, Abbas Yadegar, Hedayatollah Ghourchian
BACKGROUND: Clostridioides difficile infection (CDI) is the main etiologic agent of antibiotic-associated diarrhea. CDI contributes to gut inflammation and can lead to disruption of the intestinal epithelial barrier. Recently, the rate of CDI cases has been increased. Thus, early diagnosis of C. difficile is critical for controlling the infection and guiding efficacious therapy. APPROACH: A search strategy was set up using the terms C. difficile biomarkers and diagnosis...
April 13, 2024: Clinica Chimica Acta; International Journal of Clinical Chemistry
https://read.qxmd.com/read/38621246/infectious-diseases-what-you-may-have-missed-in-2023
#77
JOURNAL ARTICLE
Amena Alhammadi, Rasha Alshawaf, Swati Chavda, Sonya Ramondino, Mindy Schuster
In 2023, published research on COVID-19 remains prominent. The aim of this article is to highlight important developments in infectious disease evidence unrelated to COVID-19 that were published in 2023. The literature was screened for sound new evidence relevant to internal medicine specialists and subspecialists whose focus of practice is not infectious diseases. The highlighted publications relate to various organisms and patient populations. One article provides insight into the updated guidelines for the diagnosis and management of infective endocarditis...
April 16, 2024: Annals of Internal Medicine
https://read.qxmd.com/read/38617249/quinoline-based-compounds-can-inhibit-diverse-enzymes-that-act-on-dna
#78
Jujun Zhou, Qin Chen, Ren Ren, Jie Yang, Bigang Liu, John R Horton, Caleb Chang, Chuxuan Li, Leora Maksoud, Yifei Yang, Dante Rotili, Xing Zhang, Robert M Blumenthal, Taiping Chen, Yang Gao, Sergio Valente, Antonello Mai, Xiaodong Cheng
UNLABELLED: DNA methylation, as exemplified by cytosine-C5 methylation in mammals and adenine-N6 methylation in bacteria, is a crucial epigenetic mechanism driving numerous vital biological processes. Developing non-nucleoside inhibitors to cause DNA hypomethylation is a high priority, in order to treat a variety of significant medical conditions without the toxicities associated with existing cytidine-based hypomethylating agents. In this study, we have characterized fifteen quinoline-based analogs...
April 3, 2024: bioRxiv
https://read.qxmd.com/read/38616688/-inappropriate-treatment-of-asymptomatic-bacteriuria
#79
JOURNAL ARTICLE
Rama Sultan, Tomas Cazaux, Jean Regina
Asymptomatic bacteriuria is frequently encountered in clinical practice and should be treated only in pregnant women and before invasive urological procedures. Inappropriate treatment of asymptomatic bacteriuria is associated with numerous adverse effects including allergic reactions, increased antibiotics resistance and increase risk of Clostridioides difficile infection. Positive urinary culture often leads to antimicrobial treatment, irrespective of urinary symptoms. Therefore, urine analysis and culture should be performed only in symptomatic individuals or in asymptomatic individuals with a clear indication for treatment...
April 10, 2024: Revue Médicale Suisse
https://read.qxmd.com/read/38615456/an-ultrasensitive-genosensor-for-detection-of-toxigenic-and-non-toxigenic-clostridioides-difficile-based-on-a-conserved-sequence-in-surface-layer-protein-coding-gene
#80
JOURNAL ARTICLE
Sepideh Ziaei Chamgordani, Abbas Yadegar, Masoumeh Azimirad, Hedayatollah Ghourchian
Clostridioides difficile (C. difficile) is the most common agent of antibiotic-associated diarrhea, leading to intestinal infection through the secretion of two major toxins. Not all strains of this bacterium are toxigenic, but some of them cause infection via their accessory virulence factors, such as surface layer protein (SlpA). SlpA is conserved in both toxigenic and non-toxigenic strains of C. difficile. In the present work, an amplification-free electrochemical genosensor was designed for the detection of the slpA gene...
April 13, 2024: Talanta
keyword
keyword
238
4
5
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.